Bizengri Approved to Treat Some Lung, Pancreatic Cancers
Mar 26, 2025 · FDA has approved zenocutuzumab (Bizengri) to treat lung and pancreatic cancers with a rare genetic alteration called an NRG1 fusion.
FDA grants accelerated approval to zenocutuzumab-zbco
On December 4, 2024, the FDA granted accelerated approval to zenocutuzumab-zbco for non-small cell lung cancer and pancreatic adenocarcinoma.
FDA Approves Zenocutuzumab for Pancreatic and Lung Cancers With NRG1 …
Feb 6, 2025 · The FDA has granted accelerated approval to zenocutuzumab for treating patients with advanced pancreatic cancer or non-small cell lung cancer with an alteration called an NRG1 gene …
Zenocutuzumab-zbco (BIZENGRI®) Shows Durable Efficacy in
Dec 8, 2025 · In December 2024, zenocutuzumab-zbco (BIZENGRI ®) received U.S. Food and Drug Administration accelerated approval for the treatment of adults with advanced unresectable or …
Zenocutuzumab Yields Durable Responses in Treatment-Naive NRG1…
Dec 8, 2025 · Zenocutuzumab-zbco (Bizengri) showed potential in patients with treatment-naive non–small cell lung cancer (NSCLC) harboring an NRG1 gene fusion in results from a post hoc …
FDA Approves Zenocutuzumab-zbco to Treat Non-small Cell Lung Cancer …
Feb 20, 2025 · On 4 December 2024, FDA granted accelerated approval to zenocutuzumab-zbco (Bizengri®) for the treatment of adults with advanced, unresectable, or metastatic non-small cell lung …
Zenocutuzumab-zbco (BIZENGRI®) Shows Durable Efficacy in Patients …
Dec 6, 2025 · Partner Therapeutics, Inc. (PTx), a private, fully-integrated biotechnology company, announced new data from a post hoc analysis of the Phase 2 eNRGy trial (NCT02912949) …
FDA Grants Accelerated Approval to Zenocutuzumab-zbco for Non …
On December 4, 2024, the Food and Drug Administration granted accelerated approval to zenocutuzumab-zbco (Bizengri, Merus N.V.) for adults with the following: advanced, unresectable, or …
Accelerated approval for drug targeting NRG1 - Lung Cancer Research ...
Jan 14, 2025 · The good news The U.S. Food and Drug Administration (FDA) has granted accelerated approval to zenocutuzumab-zbco for the treatment of adult patients with advanced, unresectable, or …
JNCCN 360 - Non–Small Cell Lung Cancer - New Bispecific Antibody ...
On December 4, 2024, the U.S. Food and Drug Administration granted accelerated approval to the HER2 × HER3 bispecific antibody zenocutuzumab-zbco (Bizengri) for adults with advanced, …